Mer­ck KGaA touts FDA 'break­through' sta­tus, block­buster po­ten­tial in bid to woo in­vestors

Mer­ck KGaA set out to woo in­vestors to­day by bur­nish­ing its pipeline prospects and spot­light­ing its drug can­di­date in the long-run­ning race to re­lease a treat­ment for a par­tic­u­lar­ly ag­gres­sive form of lung can­cer — in­sist­ing that they have a block­buster up­side in adding new rev­enue over the next 3 years.

Mer­ck KGaA has re­ceived FDA break­through ther­a­py sta­tus for tepo­tinib, a treat­ment for MET ex­on 14 skip­ping-mu­tat­ed non-small cell lung can­cer (NSCLC), join­ing No­var­tis’ cap­ma­tinib and a Pfiz­er treat­ment (Xalko­ri) in MET NSCLC drugs with ‘break­through’ sta­tus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER